CG Oncology, Inc. (CGON)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Oncologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 27/100 (MEDIUM), 102.6 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 15.86% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- How Investors May Respond To CG Oncology (CGON) Hiring a CCO Before Potential Bladder Cancer Launch
- CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer
- CG Oncology (CGON) Stock Looks Fully Priced After A 160% Run
- Oncolytic Virus Cancer Therapy Market Expected to Expand Rapidly During the Forecast Period (2026-2036) Amid Rising Investments in Next-Generation Cancer Treatments| DelveInsight
- CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates
- CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology
- CG Oncology Stock Gains 12% in Three Months: What's Driving It?
- CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- AI-based augmentation of oncology clinical trials. — Nat Rev Clin Oncol 2026 Aug 7 PMID 42567955
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for CG Oncology, Inc..
Full CGON Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.